亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

OsteoProtect

總結: Treatment of osteoporosis by inhibitors of sphingosine-1-phosphatase (S1P)-lyase.

技術優勢: Novel approach for treating reduced bone density/stability
Specific inhibitors identified
In vivo data available

詳細技術說明: The inventors showed that S1P inhibited osteoclast function, but most importantly, stimulated osteoblasts to produce new bone. Thus, a sufficient S1P-concentration is fundamental for an osteoanabolic fine-tuning of the skelettal system. Furthermore they showed that high S1P counteracts obesity by reducing adipose tissue mass. According to the invention, in patients suffering from osteoporosis, bone formation may be facilitated (and obesity reduced) by administering inhibitors of the S1P-lyase (the key enzyme degrading S1P). An exemplary S1P-lyase inhibitor tested by the inventors is the compound 4deoxypyridoxin (DOP).

分類: - international:
A61K31/417; A61K31/4415; A61K31/4439; A61P19/10; A61P3/06; A61P3/08
- cooperative:
A61K31/417 (EP); A61K31/4415 (EP); A61K31/4439 (EP); A61P19/10 (EP); A61P3/06 (EP); A61P3/08 (EP)

欲了解更多信息，請點擊這裡